A detailed history of Royal Bank Of Canada transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 10,222 shares of PTGX stock, worth $468,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,222
Previous 5,679 80.0%
Holding current value
$468,576
Previous $164,000 115.85%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $112,030 - $158,096
4,543 Added 80.0%
10,222 $354,000
Q1 2024

May 15, 2024

SELL
$21.79 - $32.15 $256,599 - $378,598
-11,776 Reduced 67.46%
5,679 $164,000
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $132,013 - $220,242
9,396 Added 116.59%
17,455 $400,000
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $64,084 - $90,901
3,842 Added 91.11%
8,059 $134,000
Q2 2023

Aug 14, 2023

BUY
$18.02 - $29.36 $28,525 - $46,476
1,583 Added 60.1%
4,217 $116,000
Q1 2023

May 15, 2023

SELL
$10.78 - $25.38 $31,359 - $73,830
-2,909 Reduced 52.48%
2,634 $60,000
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $34,827 - $52,856
4,732 Added 583.48%
5,543 $60,000
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $2,365 - $3,524
301 Added 59.02%
811 $7,000
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $17,579 - $63,544
-2,490 Reduced 83.0%
510 $4,000
Q1 2022

May 16, 2022

SELL
$23.34 - $36.08 $164,943 - $254,977
-7,067 Reduced 70.2%
3,000 $71,000
Q4 2021

Feb 14, 2022

BUY
$17.63 - $37.1 $93,121 - $195,962
5,282 Added 110.39%
10,067 $345,000
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $18,842 - $72,298
1,455 Added 43.69%
4,785 $85,000
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $85,148 - $149,450
3,330 New
3,330 $149,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.